Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sedation - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Sedation - Pipeline Review, H1 2015', provides an overview of the Sedation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sedation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sedation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sedation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sedation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Sedation Overview 6 Therapeutics Development 7 Pipeline Products for Sedation - Overview 7 Pipeline Products for Sedation - Comparative Analysis 8 Sedation - Therapeutics under Development by Companies 9 Sedation - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Sedation - Products under Development by Companies 14 Sedation - Companies Involved in Therapeutics Development 15 Advicenne Pharma 15 AstraZeneca PLC 16 Maruishi Pharmaceutical Co., Ltd. 17 NanoMedex Pharmaceuticals, Inc. 18 Paion AG 19 Sedation - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 ABP-700 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ADV-6209 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 clonidine hydrochloride - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 MR-04A3 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 propofol - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 propofol Microemulsion - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 remimazolam - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Sedation - Recent Pipeline Updates 37 Sedation - Dormant Projects 40 Sedation - Discontinued Products 41 Sedation - Product Development Milestones 42 Featured News & Press Releases 42 Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 42 Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 42 Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 43 Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials 44 Nov 23, 2013: PAION announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation 45 Aug 05, 2013: GERMAN REGULATORY AUTHORITY APPROVED PHASE II STUDY OF REMIMAZOLAM IN INDICATION ANAESTHESIA 45 Aug 01, 2013: PAION'S PARTNER ONO STOPPED ITS DOSE FINDING, EXPLORATIVE PHASE II TRIAL IN ICU SEDATION WITH REMIMAZOLAM AND PLANS TO ADAPT THE DOSE REGIME FOR A NEW STUDY 45 May 08, 2013: Paion's Partner Ono Pharma Completes Recruitment For Phase II/III Study Of Remimazolam For General Anesthesia 46 Dec 18, 2012: Paion Receives $3m Milestone Payment From Ono Pharma Following Enrollment Of First Patient In Phase II/III Study Of Remimazolam 46 Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Number of Products under Development for Sedation, H1 2015 7 Number of Products under Development for Sedation - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Comparative Analysis by Unknown Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Sedation - Pipeline by Advicenne Pharma, H1 2015 15 Sedation - Pipeline by AstraZeneca PLC, H1 2015 16 Sedation - Pipeline by Maruishi Pharmaceutical Co., Ltd., H1 2015 17 Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2015 18 Sedation - Pipeline by Paion AG, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 27 Sedation Therapeutics - Recent Pipeline Updates, H1 2015 37 Sedation - Dormant Projects, H1 2015 40 Sedation - Discontinued Products, H1 2015 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
